Actavia Life Sciences, Inc. 是一家生物技術公司,致力於開發用於治療白血病和淋巴瘤疾病的療法。公司總部位於紐約州紐約市,目前擁有1名全職員工。該公司於2014年3月28日上市。公司致力於開發治療方法,以滿足急性骨髓性白血病(AML)及其他類型白血病和淋巴瘤尚未滿足的醫療需求。AML通常是一種老年人疾病。公司正在開發靶向LSD1基因的小分子藥物候選物,該基因控制著AML亞型發病機制的相關通路。其RASP-201是一種新型口服、選擇性可逆的賴氨酸特異性去甲基化酶(LSD1)抑制劑,該通路會阻斷細胞分化並導致AML預後不良。在AML小鼠模型中,口服RASP-201顯示出體內治療效果。其主要適應症為AML,該病可能在數週至數月內致命。
RASP stock price ended at $0 on 星期二, after dropping NaN%
On the latest trading day May 26, 2026, the stock price of RASP fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for RASP decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.